Surveillance For Clinical Use, Prescription Trends And Therapeutic Drug Monitoring (TDM) Of The Orphan Drug Rufinamide In Norway.
Phase of Trial: Phase IV
Latest Information Update: 04 Feb 2017
Price : $35 *
At a glance
- Drugs Rufinamide (Primary)
- Indications Epilepsy; Lennox-Gastaut syndrome
- Focus Adverse reactions; Therapeutic Use
- 04 Feb 2017 New trial record
- 06 Dec 2016 Results presented at the 70th Annual Meeting of the American Epilepsy Society.